Abstract
Retinopathy of prematurity (ROP) is a vasoproliferative disease of developing retinal vessels that affects premature infants and can lead to severe and irreversible visual loss if left untreated. India and some other Asian countries are in the middle of a ‘third ROP epidemic’. Blindness due to ROP is largely preventable if appropriate, adequate and accessible screening programmes are available. Screening of the premature babies is the first step in ROP management. With the increase in use of tele-screening techniques, more premature babies have been brought under the screening network both from urban and rural regions. Laser photocoagulation to the avascular retina using indirect ophthalmoscopy delivery system is the gold standard for ROP treatment and is usually done under topical anaesthesia in the Asian region in contrast to the western world. Use of intravitreal anti-vascular endothelial growth factors (VEGF) although controversial in management of ROP has been found to be effective in various Asian studies as well. ROP surgery in India and other middle-income Asian countries is largely performed only in few tertiary eye care centres. Poor visual prognosis, late presentation with advanced retinal detachments, lack of adequate number of trained paediatric retinal surgeons and paediatric anaesthetists also contribute to this problem. This current paper summarizes the Asian experience of ROP management.
早产儿视网膜病变的治疗: 在亚洲的展望
早产儿视网膜病变 (ROP) 是一种影响早产儿视网膜血管发育的血管增生性疾病, 不加以干预会导致严重且不可逆的视力丧失。如今印度和其他一些亚洲国家正处于“第三次ROP流行”的中期。ROP所致的失明大多数可通过适当、到位的和可及的筛查计划的实施进行预防。筛查早产儿是ROP管理的第一步。随着远程筛查技术应用的增加, 越来越多的早产儿已被纳入了城市及农村地区的筛查网络。相较于西方国家, 在亚洲多使用表麻下间接检眼镜传输系统对无血管区的视网膜进行激光光凝作为治疗ROP的金标准。玻璃体腔内注射抗血管内皮生长因子 (VEGF) 虽然在ROP的治疗上有争议, 但在众多亚洲研究中被认为是有效的。印度和其他中等收入的亚洲国家ROP手术大多数只在少数的三级眼科治疗中心进行。视力预后差, 视网膜脱离严重时才就诊, 缺乏足够数量训练有素的儿童视网膜外科医生和儿童麻醉师也造成了这个问题。
本文总结了亚洲在ROP管理方面的经验。
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
World Health Organization. Born too soon: the global action report on preterm birth. World Health Organization. http://www.who.int/pmnch/media/news/2012/201204_borntoosoon-report.pdf. (News release dated 2 May 2012).
Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10:S2.
Lawn JE, Davidge R, Paul VK, von Xylander S, de Graft Johnson J, Costello A, et al. Born too soon: care for the preterm baby. Reprod Health. 2013;10:S1–5.
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162–72.
Cross CW. Cost of preventing retrolental fibroplasia. Lancet. 1973;2:954–6.
Lucey JF, Dangman B. A reexamination of the role of oxygen in retrolental fibroplasia. Pediatrics. 1984;73:82–96.
Dutta S, Raghuveer T, Vinekar A, Dogra MR. Can we stop the current epidemic of blindness from Retinopathy of Prematurity? Indian Pediatr. 2016;53:80–4.
Vinekar A, Dogra MR, Sangtam T, Narang A, Gupta A. Retinopathy of prematurity in Asian Indian babies weighing greater than 1250 grams at birth: ten year data from a tertiary care center in a developing country. Indian J Ophthalmol. 2007;55:331–6.
Fierson WM. American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131:189–95.
National Neonatology Forum. Clinical practice guidelines: Retinopathy of prematurity. National Neonatology Forum. 2010. https://www.ontop-in.org/ontop-pen/Week-12-13/ROP%20NNF%20Guidelines%20.pdf.
Rashtriyabalswasthyakaryakram, Ministry of Health & Family Welfare, Government of India. Guidelines for Universal Eye Screening in Newborns including Retinopathy of Prematurity. 2017. http://www.nhm.gov.in/images/pdf/programmes/RBSK/Resource_Documents/Revised_ROP_Guidelines-Web_Optimized.pdf.
Expert group on prevention and treatment of oxygen and retinopathy in preterm infants. Guidelines for prevention and treatment of oxygen and retinopathy in preterm infants. Chin J Pediatr. 2007; 45: 672–3.
Xu Y, Zhou X, Zhang Q, Ji X, Zhang Q, Zhu J, et al. Screening for retinopathy of prematurity in China: a neonatal units-based prospective study. Investig Ophthalmol Vis Sci. 2013;54:8229–36.
Bas AY, Demirel N, Koc E, UlubasIsik D, Hirfanoglu İM, Tunc T, et al. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol. 2018. https://doi.org/10.1136/bjophthalmol-2017-311789.
Trinavarat A, Atchaneeyasakul L, Udompunturak S. Applicability of American and British criteria for screening of the retinopathy of prematurity in Thailand. Jpn J Ophthalmol. 2004;48:50–3.
Hwang JH, Lee EH, Kim EA-R. Retinopathy of prematurity among very-low-birth-weight infants in Korea: incidence, treatment, and risk factors. J Korean Med Sci. 2015;30:88–94.
Chen YH, Lien RI, Tsai S, Chang CJ, Lai CC, Chao AN, et al. Natural history of retinopathy of prematurity: two-year outcomes of a prospective study. Retina. 2015;35:141–8.
Shah VA, Yeo CL, Ling YLF, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann Acad Med Singap. 2005;34:169–78.
Aikawa H, Noro M. Low incidence of sight-threatening retinopathy of prematurity in infants born before 28 weeks gestation at a neonatal intensive care unit in Japan. Tohoku J Exp Med. 2013;230:185–90.
Vinekar A, Gilbert C, Dogra M, Kurian M, Shainesh G, Shetty B, et al. The KIDROP model of combining strategies for providing retinopathy of prematurity screening in underserved areas in India using wide-field imaging, tele-medicine, non-physician graders and smart phone reporting. Indian J Ophthalmol. 2014;62:41–9.
Vinekar A, Mangalesh S, Jayadev C, Gilbert C, Dogra M, Shetty B. Impact of expansion of telemedicine screening for retinopathy of prematurity in India. Indian J Ophthalmol. 2017;65:390–5.
Vinekar A, Azad R, Dogra MR, Narendran V, Jalali S, Bende P. The Indian retinopathy of prematurity society: a baby step towards tackling the retinopathy of prematurity epidemic in India. Ann Eye Sci. 2017;2:27.
Chen SD, Sundaram V, Wilkinson A, Patel CK. Variation in anaesthesia for the laser treatment of retinopathy of prematurity—a survey of ophthalmologists in the UK. Eye. 2007;21:1033–6.
Axer-Siegel R, Snir M, Ron Y, Friling R, Sirota L, Weinberger D. Intravitrealbevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity. Retina. 2011;31:1239–47.
Jiang J-bo, Strauss R, Luo X-qiong, Nie C, Wang YL, Zhang JW, et al. Anaesthesia modalities during laser photocoagulation for retinopathy of prematurity: a retrospective, longitudinal study. BMJ Open. 2017;7:e013344.
Şekeroğlu MA, Hekimoğlu E, Özcan B, Baş AY, Demirel N, Karakaya J. Bedside diode laser photocoagulation under remifentanil analgesia for retinopathy of prematurity: early structural outcomes. Turk J Ophthalmol. 2016;46:209–14.
Sato Y, Oshiro M, Takemoto K, Hosono H, Saito A, Kondo T, et al. Multicenter observational study comparing sedation/analgesia protocols for laser photocoagulation treatment of retinopathy of prematurity. J Perinatol. 2015;35:965–9.
Dogra MR, Vinekar A, Viswanathan K, Sangtam T, Das P, Gupta A, et al. Laser treatment for retinopathy of prematurity through the incubator wall. Ophthalmic Surg Lasers Imaging. 2008;39:350–2.
Ells AL, Gole GA, Hildebrand PL, Ingram A, Wilson CM, Williams RG. Posterior to the ridge laser treatment for severe stage 3 retinopathy of prematurity. Eye. 2013;27:525–30.
Katoch D, Sanghi G, Dogra MR, Beke N, Gupta A. Structural sequelae and refractive outcome 1 year after laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes. Indian J Ophthalmol. 2011;59:423–6.
Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol. 2013;155:159–64.
Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity in infants ≥1500 g birth weight. Indian J Ophthalmol. 2014;62:254–7.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: A Longitudinal Fluorescein Angiographic Study. Retina. 2017;37:97–111.
Ahmed AE, Channa R, Durrani J, Ali A, Ahmad K. Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Middle East Afr J Ophthalmol. 2010;17:264–7.
Xu Y, Kang X, Zhang Q, Huang Q, Lv J, Zhao P. Combination of intravitreal injection of ranibizumab and photocoagulation for the treatment of aggressive posterior retinopathy of prematurity with vitreous hemorrhage. J ophthalmol. 2016;2016:e5029278.
Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitrealbevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55:75–6.
Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011;118:176–83.
Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98:327–33.
Yonekawa Y, Wu WC, Nitulescu CE, Chan RP, Thanos A, Thomas BJ, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079–83.
Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreousbevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391–7.
Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256:479–87.
Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:e20153218.
Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37:694–701.
Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol. 2013;155:150–8.
Chuang YC, Yang CM. Scleral buckling for stage 4 retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retin. 2000;31:374–9.
Nishina S, Yokoi T, Yokoi T, Kobayashi Y, Hiraoka M, Azuma N. Effect of early vitreous surgery for aggressive posterior retinopathy of prematurity detected by fundus fluorescein angiography. Ophthalmology. 2009;116:2442–7.
Gonzales CR, Boshra J, Schwartz SD. 25-Gauge pars plicata vitrectomy for stage 4 and 5 retinopathy of prematurity. Retina. 2006;26:42–6.
Gadkari SS, Deshpande M. Variation in the vitreoretinal configuration of Stage 4 retinopathy of prematurity in photocoagulated and treatment naive eyes undergoing vitrectomy. Indian J Ophthalmol. 2017;65:846–52.
Bhende P, Gopal L, Sharma T, Verma A, Biswas RK. Functional and anatomical outcomes after primary lens-sparing pars plana vitrectomy for stage 4 retinopathy of prematurity. Indian J Ophthalmol. 2009;57:267–71.
Xu Y, Zhang Q, Kang X, Zhu Y, Li J, Chen Y, et al. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta ophthalmol. 2013;91:304–10.
Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S. Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol. 2006;142:636–43.
Gopal L, Sharma T, Shanmugam M, Badrinath SS, Sharma A, Agraharam SG, et al. Surgery for stage 5 retinopathy of prematurity: the learning curve and evolving technique. Indian J Ophthalmol. 2000;48:101–6.
Choi J, Kim JH, Kim SJ, Yu YS. Long-term results of lens-sparing vitrectomy for stages 4B and 5 retinopathy of prematurity. Korean J Ophthalmol. 2011;25:305–10.
Kondo H, Arita N, Osata M, Hayashi H, Oshima K, Uchio E. Late recurrence of retinal detachment following successful vitreous surgery for stages 4B and 5 retinopathy of prematurity. Am J Ophthalmol. 2009;147:661–6.
Wu WC, Drenser KA, Lai M, Capone A, Trese MT. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina. 2008;28:75–80.
Rathi S, Jalali S, Patnaik S, et al. Abnormal complement activation and inflammation in the pathogenesis of retinopathy of prematurity. Front Immunol. 2017;8:1868.
Kondo H, Kusaka S, Yoshinaga A, Uchio E, Tawara A, Tahira T. Genetic variants of FZD4 and LRP5 genes in patients with advanced retinopathy of prematurity. Mol Vis. 2013;19:476–85.
CDC. Developing an effective evaluation report. CDC; 2013. https://www.cdc.gov/eval/materialsDevelopingAnEffectiveEvaluationReport_TAG508.pdf.
Vinekar A, Dogra MR, Jayadev C. Evaluation of a new, low-cost, portable, wide-field digital retinal camera, “Neo” for screening infants or retinopathy of prematurity—a prospective, multi-center, validation report in Asian Indian infants. Investig Ophthalmol Vis Sci. 2016; 57. http://iovs.arvojournals.org/article.aspx?articleid=25557805&resultClick=1#139816184.
WISE-ROP program. http://www.digihealthplatform.com/project/wise-rop-program/.
Gilbert C, Wormald R, Fielder A, Deorari A, Zepeda-Romero LC, Quinn G, et al. Potential for a paradigm change in the detection of retinopathy of prematurity requiring treatment. Arch Dis Child Fetal Neonatal Ed. 2016;101:F6–9.
Wilkinson AR, Haines L, Head K, Fielder AR. Guideline Development Group of the Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists et al. UK retinopathy of prematurity guideline. Eye. 2009;23:2137–9.
Al Amro SA, Al Aql F, Al Hajar S, Al Dhibi H, Al Nemri A, Mousa A, et al. Practical guidelines for screening and treatment of retinopathy of prematurity in Saudi Arabia. Saudi J Ophthalmol. 2018;32:222–6.
Sanghi G, Dogra MR, Vinekar A, Gupta A. Frequency-doubled Nd:YAG (532 nm green) versus diode laser (810 nm) in treatment of retinopathy of prematurity. Br J Ophthalmol. 2010;94:1264–5.
Jalali S, Azad R, Trehan HS, Dogra MR, Gopal L, Narendran V. Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia. Indian J Ophthalmol. 2010;58:509–15.
Uparkar M, Sen P, Rawal A, Agarwal S, Khan B, Gopal L. Laser photocoagulation (810 nm diode) for threshold retinopathy of prematurity: a prospective randomized pilot study of treatment to ridge and avascular retina versus avascular retina alone. Int Ophthalmol. 2011;31:3–8.
Parvaresh MM, Falavarjani KG, Modarres M, Nazari H, Saiepour N. Transscleral diode laser photocoagulation for type 1 prethreshold retinopathy of prematurity. J Ophthalmic Vis Res. 2013;8:298–302.
Vinekar A, Jayadev C, Mangalesh S, Kumar AK, Bauer N, Capone JrA, et al. Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina. 2015;35:2130–6.
Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–5.
Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity—27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015;253:1677–83.
Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124:1156–64.
Yu YS, Kim SJ, Kim SY, Choung HK, Park GH, Heo JW. Lens-sparing vitrectomy for stage 4 and stage 5 retinopathy of prematurity. Korean J Ophthalmol. 2006;20:113–7.
Wu WC, Lai CC, Lin RI, Wang NK, Chao AN, Chen KJ, et al. Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity. Arch Ophthalmol. 2011;129:1326–31.
Gadkari S, Kamdar R, Kulkarni S, Kakade N, Taras S, Deshpande M. Vitreoretinal surgery for advanced retinopathy of prematurity: presentation and outcomes from a developing country. Can J Ophthalmol. 2015;50:54–60.
Shah PK, Prabhu V, Narendran V. Outcomes of transconjuctival sutureless 27-gauge vitrectomy for stage 4 retinopathy of prematurity. World J Clin Pediatr. 2018;7:62–6.
Shah PK, Narendran V, Kalpana N, Tawansy KA. Anatomic and visual outcomes of stage 4 & 5 ROP. Eye. 2009;23:176–80.
Karacorlu M, Hocaoglu M, Sayman Muslubas I, Arf S. Long-term functional results following vitrectomy for advanced retinopathy of prematurity. Br J Ophthalmol. 2017;101:730–4.
Kono T, Oshima K, Fuchino Y. Surgical results and visual outcomes of vitreous surgery for advanced stages of retinopathy of prematurity. Jpn J Ophthalmol. 2000;44:661–7.
Cusick M, Charles MK, Agron E, Sangiovanni JP, Ferris FL 3rd, Charles S. Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina. 2006;26:729–35.
Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28:839–46.
Agarkar S, Desai R, Singh S, Jaisankar D, Bhende P, Raman R. Influence of laser versus lens-sparing vitrectomy on myopia in children with retinopathy of prematurity. Indian J Ophthalmol. 2017;65:841–5.
Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye. 2014;28:1080–7.
Yang CS, Wang AG, Sung CS, Hsu WM, Lee FL, Lee SM. Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years. Eye. 2010;24:14–20.
Shah PK, Ramakrishnan M, Sadat B, Bachu S, Narendran V, Kalpana N. Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity. Oman J Ophthalmol. 2014;7:116–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sen, P., Wu, WC., Chandra, P. et al. Retinopathy of prematurity treatment: Asian perspectives. Eye 34, 632–642 (2020). https://doi.org/10.1038/s41433-019-0643-4
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41433-019-0643-4
This article is cited by
-
The aftermath of retinopathy of prematurity blindness
Eye (2025)
-
Current and future roles of artificial intelligence in retinopathy of prematurity
Artificial Intelligence Review (2025)
-
Computer-aided detection of retinopathy of prematurity severity assessment via vessel tortuosity measurement in preterm infants’ fundus images
Eye (2024)
-
Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity
Graefe's Archive for Clinical and Experimental Ophthalmology (2024)
-
Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial
Japanese Journal of Ophthalmology (2024)
